Several investment banks slashed their ratings on Amgen shares, following the disclosure that a U.S. advisory panel called for marketing restrictions on popular anemia drugs sold by Amgen and J&J. Mike Huckman, CNBC pharmaceuticals reporter, has the details.
Topics:
Biotechnology | Pharmaceuticals
COMMENTS
Thank you for joining our discussion. Your comment has been posted.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT